Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
Abbott has introduced the mixing of its Precision Oncology portfolio into Flatiron Well being’s cloud-based digital medical document (EMR) platform, OncoEMR.
The combination permits oncology suppliers to digitally order Abbott checks, monitor progress and entry outcomes inside their present scientific workflow on OncoEMR.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
Oncology physicians can entry Abbott checks equivalent to Oncodetect, OncoExTra, Oncotype DX Breast Recurrence Rating and Riskguard via a single interface.
Suppliers can order checks individually or together and obtain standing updates.
This integration is designed to assist remedy selections at a number of phases of most cancers care whereas lowering administrative burdens for physicians.
The partnership will make Abbott’s Precision Oncology checks obtainable throughout the Flatiron community of greater than 1,600 group most cancers care facilities within the US.
Flatiron vice chairman and normal supervisor of healthcare point-of-care options Quincy Weatherspoon mentioned, “We need to make it simpler for physicians to entry the suitable info on the proper time of care.
“By integrating Abbott’s Precision Oncology portfolio instantly into OncoEMR, we’re lowering friction within the workflow and serving to suppliers transfer quicker – from check ordering to remedy selections. That is what it appears to be like prefer to deliver extra linked, data-driven care to the purpose of care.”
Abbott Precision Oncology vice chairman Brian Baranick mentioned, “For group oncology practices, the place most most cancers care is delivered, this removes a key barrier to accessing our portfolio on the level of care, expediting remedy selections and enabling extra knowledgeable, personalised affected person care.”
Earlier this month, Abbott introduced outcomes from the FreeDM2 randomized managed trial, which confirmed that improved glucose outcomes have been noticed in people utilizing the FreeStyle Libre steady glucose monitoring expertise for kind 2 diabetes.
